This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
by Zacks Equity Research
While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.
Should You Buy, Sell or Hold Gilead Sciences (GILD) Before Q2 Earnings?
by Ekta Bagri
While Gilead (GILD) has been under pressure year to date due to pipeline setbacks, holding on to this biotech giant should be prudent at current levels.
Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Merus (MRUS) delivered earnings and revenue surprises of -6.58% and 23.94%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Merus (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?
by Ekta Bagri
While Gilead (GILD) has been reeling under pressure year to date due to pipeline setbacks, holding on to this biotech giant will be prudent at current levels.
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
by Zacks Equity Research
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 14.49% and 2.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
by Zacks Equity Research
Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prothena (PRTA) Surges 12.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wall Street Analysts See a 52.96% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 53% in Merus N.V. (MRUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 87.71%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Merus N.V. (MRUS) points to an 87.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Merus N.V. (MRUS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Merus N.V. (MRUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See an 85.36% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 85.4% in Merus N.V. (MRUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 83.26%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 83.3% upside potential for Merus N.V. (MRUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of 0.92% and 5.58%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
GSK (GSK) Moves 5.5% Higher: Will This Strength Last?
by Zacks Equity Research
GSK (GSK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.